Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia

• Status: Completed
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the addition of tobramycin inhalation treatment to standard intravenous therapy in the treatment of ventilator associated pneumonia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erasmus Medical Center
• Collaborator: Chiesi Farmaceutici S.p.A.
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Tobramycin

Criteria

Inclusion Criteria:

• Mechanical ventilation 48 hours or more

• New or progressive radiologic pulmonary infiltrate

Together with at least two of the following three criteria (< 24 h):

• temperature >38°C

• leukocytosis >12,000/mm3 or leucopenia <4,000/mm3

• purulent respiratory secretions

Exclusion Criteria:

• patients with allergy to tobramycin

• pregnancy

• expected to die within 72 hours after enrollment